论文部分内容阅读
目的:评价培哚普利对慢性心力衰竭(CHF)患者血浆血管紧张素Ⅱ(AngⅡ)和纤溶酶原激活物抑制物-1(PAI-1)水平的影响。方法:分别采用放射免疫法和酶联免疫吸附法测定60例CHF患者及20例健康人(正常对照组)血浆AngⅡ、PAI-1水平。60例CHF患者随机分为常规治疗组(30例)和培哚普利组(30例)。培哚普利组在常规治疗基础上加用培哚普利2~4mg,qd。治疗2周后复测血浆AngⅡ、PAI-1水平。结果:治疗前CHF患者血浆AngⅡ、PAI-1水平比正常对照组明显增高(P<0.01)。治疗2周后,培哚普利组血浆AngⅡ、PAI-1水平比常规治疗组明显降低(P<0.01)。结论:培哚普利不仅可抑制肾素-血管紧张素系统,而且可改善内源性纤溶功能。
Objective: To evaluate the effect of perindopril on plasma levels of angiotensin Ⅱ (Ang Ⅱ) and plasminogen activator inhibitor-1 (PAI-1) in patients with chronic heart failure (CHF). Methods: Plasma levels of AngⅡ and PAI-1 in 60 CHF patients and 20 healthy controls (normal control group) were determined by radioimmunoassay and enzyme-linked immunosorbent assay respectively. Sixty CHF patients were randomly divided into routine treatment group (30 cases) and perindopril group (30 cases). Perindopril group with routine treatment based on the addition of perindopril 2 ~ 4mg, qd. Plasma Ang Ⅱ and PAI-1 levels were measured after 2 weeks of treatment. Results: The plasma levels of AngⅡ and PAI-1 in CHF patients before treatment were significantly higher than those in normal controls (P <0.01). After 2 weeks of treatment, the levels of plasma AngⅡ and PAI-1 in perindopril group were significantly lower than those in routine treatment group (P <0.01). CONCLUSION: Perindopril not only inhibits the renin-angiotensin system, but also improves endogenous fibrinolysis.